


# Why Take A Chance With Pneumococcal Infection?



## Help Prevent It With *Pneumovax*.

### Dramatic impact in children < 1 year old.<sup>1,2,3</sup>



—Adapted from Black SB, *et al.*<sup>1</sup>

**Reduction in invasive pneumococcal disease compared with the 4-year prelicensure period in children < 1 year old.**

<sup>2</sup>Based on US data of postlicensure surveillance study conducted within the Northern California Kaiser Permanente population from April 2000 through March 2001.

<sup>3</sup>Mean incidence of invasive pneumococcal disease caused by vaccine serotypes.

*Pneumovax* [Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)] is indicated for the active immunization of infants and children from 6 weeks until 9 years of age against invasive disease, pneumonia and otitis media caused by *S. pneumoniae* due to the capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F). *Pneumovax* is contraindicated in patients with coagulation disorders and who are hypersensitive to diphtheria toxoid. This vaccine is not intended to be used for the treatment of active infection. *Pneumovax* will not help to protect against pneumococcal disease other than that caused by the seven serotypes included in the vaccine.

**References:** 1. Black SB, *et al. Pediatr Infect Dis J* 2001;20:1105-7. 2. Health Canada, Canada Communicable Disease Report (CCDR), 15 January 2002; Vol 28, ACS-2. 3. Canadian Immunization Guide, Health Canada. 2002. Sixth Edition. 4. *Pneumovax* Product Monograph, Wyeth-Ayerst Canada Inc., 2001.

### Watch This Box For New Information

The National Advisory Committee on Immunization (NACI) now recommends Pneumococcal Conjugate Vaccine for routine administration to children <5 years of age.<sup>2,35</sup>

- ✓ Favorable safety and tolerability profile in a multicentre trial involving 37,816 infants.<sup>41</sup>
- ✓ Only mild and transient local reactions without serious side effects.<sup>2</sup>

<sup>41</sup>The most frequently reported adverse events in infants and toddlers, within 2-3 days following immunization, included fever ( $\geq 38.0^{\circ}\text{C}$ ), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, injection site reactions and rash or hives. Incidence may vary with age and concomitantly administered vaccines.

<sup>35</sup>Please refer to the NACI statement for complete recommendations.

Visit: [www.hc-sc.gc.ca/pphb-dgspspp/publicat/ccdr-rmtc/02vol28/28sup/acs2.html](http://www.hc-sc.gc.ca/pphb-dgspspp/publicat/ccdr-rmtc/02vol28/28sup/acs2.html)

*Pneumovax*<sup>®</sup> The World's First and Only  
Pneumococcal Conjugate Vaccine  
for Infants and Children

Wyeth<sup>®</sup> Member

© 2003 Wyeth Canada  
Montréal, Canada H4R 1J6

*Pneumovax*<sup>®</sup> is a registered trademark of Wyeth-Ayerst Canada, Inc.